Abstract: This invention relates to a method of imaging amyloid deposits and to labeled compounds, and methods of making labeled compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.

Abstract: The present invention relates to compounds of formula I wherein R1, R2, R3, R4 and m are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical compositions comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

Abstract: Processes comprising: providing a reactive distillation column having an upper region, a middle region and a lower region; feeding ethylene glycol and an aqueous formaldehyde solution into the reactive distillation column in the middle region of the reactive distillation column; reacting the ethylene glycol and the aqueous formaldehyde solution in the reactive distillation column in the presence of a catalyst to form dioxolane; removing a product stream comprising dioxolane in an amount of at least 75% by weight from the upper region of the reactive distillation column; and removing a bottom stream comprising one or more components having boiling points higher than dioxolane from the lower region of the reactive distillation column.

Abstract: The invention relates to a process for the preparation of stiripentol particles having a defined particle size distribution.

Abstract: The invention provides a process for the mixing of an oxidant having explosive potential with a hydrocarbon material, which comprises conveying a first stream comprising the hydrocarbon material and a second stream comprising the oxidant into a microchannel apparatus, allowing mixing to occur, and withdrawing the mixture. The process is useful for the preparation of ethylene oxide.

Abstract: A supported amorphous alloy catalyst, which is supported on a macroporous carrier-expanded graphite. The catalyst contains a Ni—B amorphous alloy (5 to 50% by weight) and a transition inductive metal (0.1 to 10% by weight). The diameter of expanded graphite carrier particles is 80-800 ?m. Its BET specific surface area is 10-100 m2/g. The catalyst is prepared by metal inductive electroless powder plating method which is easy to apply to industrial production. Ni—B clusters of prepared catalyst are well dispersed on the support. The catalyst shows high catalytic activity and good mechanical property, and is safe to use with low manufacturing costs.

Abstract: The present invention discloses the ascorbic acid derivatives. The inventive molecules that combine with one or two hydrophilic headgroups connected by a hydrophobic spacer can increase skin penetration.

Abstract: A process for making propylene oxide from propylene is disclosed. The process comprises reacting propylene, oxygen, and hydrogen in the presence of a catalyst and a solvent to produce a reaction mixture comprising propylene oxide. Separation of propylene, oxygen, hydrogen, and propylene oxide from the reaction mixture results in a residual mixture comprising methanol. A portion of the residual mixture is recycled to the reaction. A portion of the residual mixture is distilled to generate a distilled methanol stream, which is recycled to the reaction.

Abstract: There is provided a catalyst carrier comprising a refractory inorganic material having a sodium solubilization rate no greater than 5 ppmw/5 minutes. There is further a catalyst comprising a refractory inorganic material carrier having a sodium solubilization rate no greater than 5 ppmw/5 minutes; and one or more catalytically reactive metals deposited on said carrier. There is also provided a catalyst suitable for the vapor phase production of alkylene oxide from olefins and oxygen comprising an alumina-based carrier having a sodium solubilization rate no greater than 5 ppmw/5 minutes; and catalytically reactive silver deposited on said carrier.

Abstract: A high-purity cycloaliphatic diepoxy compound of General Formula (II) is an epoxidized product of a cycloaliphatic diolefinic compound of General Formula (I) having an isomer content as detected in gas chromatography (GC) of 15% or less: wherein X represents a bivalent group selected from the group consisting of, for example, O, S, —SO—, —SO2—, —CH2—, and —C(CH3)2—; and R1 to R18 may be the same as or different from each other and each represent hydrogen atom, a halogen atom, a hydrocarbon group which may contain oxygen atom or a halogen atom, or an alkoxy group which may be substituted. Such a high-purity cycloaliphatic diepoxy compound is prepared by producing the cycloaliphatic diolefinic compound through distillation, epoxidizing the compound with an aliphatic percarboxylic acid containing substantially no water, carrying out desolvation, and further purifying the epoxidized compound through distillation.

Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.

Abstract: A modular construction micro-reactor with parallel microchannels on fluid guide plates for chemical reactions, but not for evaporation purposes is known. A modular construction falling film evaporator is disclosed, comprising a stack of alternate gap-like evaporation chambers and sheet-like evaporator modules with an assembly of parallel microchannels, whereby the evaporation chambers are open above and/or below across the whole width of the module and the stack is arranged in a container. The falling film evaporator is used in a method for obtaining a gaseous phase from a liquid medium on a technical scale and is suitable for the concentration of thermolabile solutions and rapidly adjustable production of a gas stream.

Abstract: The present invention relates to a compound of the following formula: where R1-R6, R10, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.

Abstract: The present invention provides a chiral ligand, represented by a formula or its enantiomer: X and X? can be independently O, NH, NR, NCOR or S; each of Z1-Z7 and Z1?-Z7? can be independently H, alkyl, aryl, substituted alkyl, substituted aryl, alkoxyl, aryloxyl, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, hetereoaryl, or a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent Z groups or any two adjacent Z? groups; Y and Y? can be independently OH, OR, NH2, NHR, NR2, SH, PR2, OPR2, NHPR2, OP(OR)2, COOH, COOR, CONHR, or a linking group formed from Y and Y? groups together. Processes of preparing these ligands, catalysts that employ them and methods of using the catalysts are also provided.

Abstract: A carrier for a catalyst useful for the epoxidation of an olefin which comprises an inert, refractory solid carrier is provided. The carrier has no or little absolute volume from small pores, of less than 1 micrometer, and large pores, of above 5 micrometer. By “no or little absolute volume from small pores of less than 1 micron” it is meant that the pore volume of such pores is less than 0.20 ml/g. By “no or little absolute volume from large pores of above 5 micron” it is meant that the pore volume of such pores is less than 0.20 ml/g. The invention further provides a catalyst useful for the epoxidation of an olefin supported on such a carrier and a process for the oxidation of an olefin, especially ethylene, to an olefin oxide, especially ethylene oxide.

Abstract: Compounds of Formula (1) and their pharmaceutically acceptable salts are described: Formula (1) Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

Abstract: (5-Benzyl-3-furyl)methyl 2,2-dimethyl-3-((E)-2-cayano-3-methoxy-3-oxo-1-propenyl)cyclopropanecarboxylate has an excellent pesticidal activity, and a pesticidal composition comprising it as an active ingredient is useful for controlling pests.

Abstract: A method of oxidizing hydroxymethylfurfural (HMF) includes providing a starting material which includes HMF in a solvent comprising water into a reactor. At least one of air and O2 is provided into the reactor. The starting material is contacted with the catalyst comprising Pt on a support material where the contacting is conducted at a reactor temperature of from about 50° C. to about 200° C. A method of producing an oxidation catalyst where ZrO2 is provided and is calcined. The ZrO2 is mixed with platinum (II) acetylacetonate to form a mixture. The mixture is subjected to rotary evaporation to form a product. The product is calcined and reduced under hydrogen to form an activated product. The activated product is passivated under a flow of 2% O2.

Abstract: A reactor and heat exchanger assembly is provided with the heat exchanger integrally affixed to the reactor exit head and adapted to immediately cool reactor gases from the reactor.

Abstract: A method to achieve a controlled start-up temperature of an expoxidation process which exceeds the maximum achievable temperature of the epoxidation reactor relative to using an external heat source. The method of the present invention employs an oxidation reaction within the reactor to bring the temperature of the reactor to a temperature that is suitable for conditioning a high selectivity catalyst. The method of the present invention includes first bringing a reactor including a high selectivity catalyst to a first temperature using the external heat source to the reactor, while staying within the reactor design limitations and maintaining a gas flow to the reactor that is within 25 to 100% of the design rates. Once the reactor has achieved the first temperature, at least an olefin, e.g., ethylene, and then oxygen are introduced to the reactor feed gas.